West Pharmaceutical Services (WST) FY 2025 Conference September 03, 2025 03:00 PM ET Company ParticipantsBrandon Couillard - Managing DirectorRobert McMahon - SVP & CFOJohn Sweeney - VP - IRBrandon CouillardAll right. Good afternoon. Welcome to the Wells Fargo Healthcare Conference. I'm Brandon Couillard. I cover life science tools and diagnostics here at the firm.It's a real pleasure to have Wes Pharma with us at the conference this year. Joining us to my left, new CFO, Bob McMahon and Head of IR, John Swe ...

West Pharmaceutical Services (WST) FY 2025 Conference September 03, 2025 03:00 PM ET Speaker0All right. Good afternoon. Welcome to the Wells Fargo Healthcare Conference. I'm Brandon Couillard. I cover life science tools and diagnostics here at the firm.It's a real pleasure to have Wes Pharma with us at the conference this year. Joining us to my left, new CFO, Bob McMahon and Head of IR, John Sweeney. Thank you both for being here.Speaker1Thanks, Brandon. It's a pleasure to be here. I was going say be kind t ...

EXTON, Pa., Aug. 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at multiple investor conferences in September. Here are the details of the presentations: About West West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the ...

Core Viewpoint - West Pharmaceutical Services (WST) has shown a significant price increase of 11.1% over the past four weeks, with a mean price target of $316.82 indicating a potential upside of 28.7% from the current price of $246.2 [1] Price Targets and Analyst Consensus - The average price target for WST is based on 11 short-term estimates, ranging from a low of $260.00 to a high of $355.00, with a standard deviation of $34.23, suggesting variability in analyst predictions [2] - The lowest estimate indicates a 5.6% increase, while the highest suggests a 44.2% upside, highlighting the range of analyst expectations [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about WST's earnings prospects, as evidenced by a trend of higher EPS estimate revisions, which correlates with potential stock price increases [11] - Over the last 30 days, four estimates for the current year have been revised upward, resulting in a 7.6% increase in the Zacks Consensus Estimate [12] - WST holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, as empirical research shows that they rarely indicate actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors are advised to treat price targets with skepticism and not rely solely on them for investment decisions [10]

The Zacks Medical - Dental Supplies industry in the Medical sector is reflecting weakness amid rising tariffs by the U.S. government on its trading partners, especially China. The tariffs are likely to stay and continue to impact industry sales for the rest of 2025, although several countries are negotiating a trade deal with the United States, which may lead to lower rates for specific countries. The tariffs are also leading to a rise in costs, disrupting supply chains and strategic supply shifts in the de ...

Core Viewpoint - West Pharmaceutical Services (WST) has shown a significant price increase of 13.7% over the past four weeks, with analysts projecting a mean price target of $316.82, indicating a potential upside of 25.3% from the current price of $252.94 [1] Price Targets and Analyst Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $34.23, suggesting variability in analyst predictions. The lowest estimate is $260.00 (2.8% increase), while the highest is $355.00 (40.4% increase) [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding WST's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. Four estimates have increased over the last 30 days, with no negative revisions, leading to a 7.8% increase in the Zacks Consensus Estimate [11][12] - WST holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Caution on Price Targets - While price targets are commonly referenced by investors, they can often mislead. Empirical research suggests that price targets rarely indicate actual stock price movements, and analysts may set overly optimistic targets due to business incentives [7][8][10]

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of West Pharmaceutical Services, Inc. (NYSE: WST) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at West Pharmaceutical caused the company to misrepresent or fail to disclose that (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product desto ...

Core Viewpoint - West Pharmaceutical Services (WST) has received a Zacks Rank 1 (Strong Buy) upgrade, indicating a positive outlook for its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for West Pharmaceutical indicates expected earnings of $6.61 per share for the fiscal year ending December 2025, showing no year-over-year change [9]. - Over the past three months, analysts have raised their earnings estimates for West Pharmaceutical by 7.8% [9]. Zacks Rating System - The Zacks rating system is based solely on a company's changing earnings picture, tracking EPS estimates from sell-side analysts [2]. - The system classifies stocks into five groups, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [10][11]. Market Implications - Rising earnings estimates and the Zacks upgrade suggest an improvement in West Pharmaceutical's underlying business, which could lead to higher stock prices as investors respond positively [6]. - The correlation between earnings estimate revisions and near-term stock movements highlights the potential for West Pharmaceutical to outperform the market [7].

Group 1: Stock Highlights - Calix, Inc. (CALX) has a Zacks Rank 1 with a 25.6% increase in the current year earnings estimate over the last 60 days and a share price gain of 35.9% in the last three months compared to the S&P 500's 14.9% [1] - Medpace Holdings, Inc. (MEDP) also holds a Zacks Rank 1, with a 10.1% increase in the current year earnings estimate over the last 60 days and a share price gain of 46.1% in the last three months compared to the S&P 500's 14.9% [2] - West Pharmaceutical Services, Inc. (WST) maintains a Zacks Rank 1, with a 5.3% increase in the current year earnings estimate over the last 60 days and a share price gain of 23.4% in the last three months compared to the S&P 500's 14.9% [3] Group 2: Momentum Scores - Calix, Inc. has a Momentum Score of A, indicating strong momentum characteristics [1] - Medpace Holdings, Inc. also possesses a Momentum Score of A, reflecting its robust performance [2] - West Pharmaceutical Services, Inc. carries a Momentum Score of A, showcasing its positive momentum [3]

Core Insights - The author has a strong educational background with a master's degree in Analytics and a bachelor's degree in Accounting, indicating a solid foundation for investment analysis [1] - The author has over 10 years of experience in the investment arena, starting as an analyst and progressing to a management role, showcasing a deep understanding of the industry [1] - The author expresses a personal interest in dividend investing, suggesting a focus on income-generating investments [1] Company and Industry Summary - The author holds long positions in several companies including CTAS, JNJ, WST, O, HRL, LOW, PEP, and ROP, indicating a diversified investment strategy [2] - The article reflects the author's personal opinions and does not involve compensation from the companies mentioned, suggesting an independent analysis [2] - The disclosure emphasizes that past performance is not indicative of future results, highlighting the inherent uncertainties in investment decisions [3]